Brent Reeves
Internal Medicine · Fort Smith, ARNPI 1306130034
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,489 and has fallen 95.5% since, to $68 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$829
- Novo Nordisk$749
- Amgen$578
- AstraZeneca$554
- Pfizer$495
- Amarin Pharma, Inc.$446
- plus $3K from 36 others
What the payments were for
- Food & beverage$6,43599%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,495 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $51,781 |
| MounjaroTirzepatide | 39 | $42,106 |
| FarxigaDapagliflozin Propanediol | 28 | $26,265 |
| OzempicSemaglutide | 20 | $23,529 |
| XareltoRivaroxaban | 15 | $19,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,293 |
| MyrbetriqMirabegron | 16 | $13,147 |
| Potassium Chloride | 58 | $1,424 |
| Omeprazole | 110 | $1,196 |
| Gabapentin | 73 | $1,153 |
| Omega-3 Acid Ethyl Esters | 12 | $1,132 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,111 |
| SynthroidLevothyroxine Sodium | 12 | $1,014 |
| Olmesartan Medoxomil | 32 | $947 |
| Nebivolol Hcl | 11 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $495 | $51,78174 claims |
| Lilly USA, LLCMounjaro | $293 | $42,10639 claims |
| AstraZenecaFarxiga | $554 | $26,26528 claims |
| Novo NordiskOzempic | $749 | $23,52920 claims |
| Johnson & JohnsonXarelto | $247 | $19,61615 claims |
| GSKTrelegy Ellipta | $214 | $18,29323 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $13,14716 claims |
| AbbVieSynthroid | $829 | $1,01412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Fort Smith
- Tyree SealsFort Smith$14K
- Hubert LandersFort Smith$7K
- Beena SyedFort Smith$6K
- Kendall WagnerFort Smith$6K
- Sumer PhillipsFort Smith$6K
- Becky YarboroughFort Smith$6K
- Zain SharifFort Smith$5K
- David PyleJonesboro$93K
- Aaron StrobelLittle Rock$32K
- Stuart BensonRogers$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.